This bill amends the Idaho Code to update the classifications of controlled substances, particularly focusing on Schedule I, Schedule III, and Schedule IV substances. It introduces numerous new substances to Schedule I, including various fentanyl analogs and synthetic opioids, such as Alpha'-methyl butyryl fentanyl and 3-Furanyl fentanyl, while removing outdated entries. The bill also adds new synthetic cannabinoids and psychoactive compounds to the controlled substances list, including Cumyl PeGACLONE and 5F-EDMB-PINACA, and modifies the lists of depressants and stimulants by including new substances like Clonazolam and 3-MMC, while deleting less relevant ones. These amendments aim to enhance the state's regulatory framework to address the growing concerns surrounding opioid misuse and the evolving landscape of synthetic drug use.

Additionally, the bill revises the classification of anabolic steroids, introducing new substances such as 2alpha,17alpha-dimethyl-17beta-hydroxy-5beta-androstan-3-one and 4-chloro-17alpha-methyl-androsta-1,4-diene-3,17beta-diol, while removing others like 1-androstenediol. It specifies that anabolic steroids approved by the FDA for nonhuman species will not be classified as controlled substances. The bill establishes penalties for the illegal prescription, dispensing, or sale of anabolic steroids and human growth hormones for performance enhancement, classifying these actions as felonies. The bill is set to take effect on July 1, 2025, following an emergency declaration, reflecting the urgency of addressing these public health issues.

Statutes affected:
Bill Text: 37-2705, 37-2709, 37-2711